Agios Pharma (8AP) Price & Analysis

0 Followers

8AP Stock Chart & Stats

€29.00

-€0.80(-2.56%)

At close: Jul 30 4:00 PM EDT

€29.00

-€0.80(-2.56%)

Day’s Range― - ―

52-Week Range€19.70 - €38.80

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€1.63B

Enterprise Value€1.62B

Total Cash (Recent Filing)€617.58M

Total Debt (Recent Filing)€31.17M

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Nov 05, 2026

EPS Estimate

-1.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-7.01

Shares Outstanding59,701,880

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)1.32

Price to Sales (P/S)29.21

P/FCF Ratio-4.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€40.34

Price Target Upside39.09% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-5.15

Revenue Forecast (FY)€157.77M

Bulls Say, Bears Say

Bulls Say

Commercial Revenue GrowthStrong revenue growth and Q2 launch performance indicate that Agios is converting its approved-product opportunity into commercial sales. Continued adoption can broaden the revenue base, improve operating leverage over time, and support investment in additional hematology indications.

Strong Liquidity And Low LeverageAgios has substantial liquidity relative to its low debt burden, providing financial flexibility to fund clinical development, commercial expansion, and regulatory activities. This balance-sheet capacity reduces near-term financing pressure while the company works toward improving profitability.

Pipeline AdvancementMultiple programs are advancing across hematology and metabolic disease, giving Agios opportunities to diversify beyond its current commercial product. Progress into later-stage development can expand the addressable portfolio and create additional future revenue opportunities.

Bears Say

Deep Losses And Cash BurnPersistent losses and substantial negative cash flow show that current operations do not yet fund the company’s development and commercial activities. Continued spending at this level can consume liquidity and increase the importance of future product growth or external financing.

High Operating ExpensesRising research and selling expenses are necessary to advance programs and support commercialization, but they currently widen the gap between revenue and operating costs. Unless investment produces sustained sales growth or pipeline value, operating leverage and earnings improvement may remain limited.

Delayed Sickle-cell Regulatory CatalystThe extended review timeline postpones potential regulatory validation and the opportunity to commercialize mitapivat in sickle cell disease. This delays a possible expansion of the addressable market and prolongs dependence on existing products and pipeline execution.

Agios Pharma News

Agios FDA review delay just ‘timing setback,’ says H.C. Wainwright

H.C. Wainwright is surprised that the FDA extended the review period for Agios Pharmaceuticals (AGIO)’ mitapivat in sickle...

2d ago

AGIO

Agios Pharmaceuticals announces new PDUFA goal date for mitapivat sNDA

Agios Pharmaceuticals (AGIO) announced that the FDA has extended the Prescription Drug User Fee Act, or PDUFA, goal...

2d ago

AGIO

Agios Pharmaceuticals assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao assumed coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $55 price...

3d ago

AGIO

Agios Pharmaceuticals price target lowered to $37 from $39 at Truist

Truist lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $37 from $39 and keeps a Buy...

25d ago

AGIO

Agios Pharmaceuticals price target raised to $50 from $46 at BofA

BofA raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $50 from $46 and keeps a Buy...

1M ago

AGIO

Agios Pharmaceuticals Signals Momentum Amid Ongoing Losses

Agios Pharmaceuticals (($AGIO)) has held its Q2 earnings call. Read on for the main highlights of the call....

3M ago

AGIO

Agios Pharmaceuticals price target raised to $52 from $46 at Citi

Citi raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $52 from $46 and keeps a Buy...

3M ago

AGIO

Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46

Bank of America Securities analyst Alec Stranahan has reiterated their bullish stance on AGIO stock, giving a Buy...

3M ago

AGIO

Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating

TD Cowen analyst Marc Frahm has maintained their bullish stance on AGIO stock, giving a Buy rating yesterday....

3M ago

AGIO

Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $55 from $52 and keeps a...

3M ago

AGIO

Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)

Reports Q2 revenue $44.75M, consensus $26.7M. Cash, cash equivalents and marketable securities were $964.8M as of June 30,...

3M ago

AGIO

AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Agios Pharmaceuticals (AGIO) is scheduled to report 2nd quarter earnings on 07/30/2026, before the market opens. Regarding Q2...

3M ago

AGIO

Agios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum

Bank of America Securities analyst Alec Stranahan has maintained their bullish stance on AGIO stock, giving a Buy...

3M ago

AGIO

Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $52 from $54...

3M ago

AGIO

8AP FAQ

What was Agios Pharma’s price range in the past 12 months?

Agios Pharma lowest stock price was €19.70 and its highest was €38.80 in the past 12 months.

What is Agios Pharma’s market cap?

Agios Pharma’s market cap is €1.63B.

When is Agios Pharma’s upcoming earnings report date?

Agios Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.

How were Agios Pharma’s earnings last quarter?

Agios Pharma released its earnings results on Jul 30, 2026. The company reported -€1.508 earnings per share for the quarter, missing the consensus estimate of -€1.477 by -€0.031.

Is Agios Pharma overvalued?

According to Wall Street analysts Agios Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Agios Pharma pay dividends?

Agios Pharma does not currently pay dividends.

What is Agios Pharma’s EPS estimate?

Agios Pharma’s EPS estimate is -1.11.

How many shares outstanding does Agios Pharma have?

Agios Pharma has 59,701,880 shares outstanding.

What happened to Agios Pharma’s price movement after its last earnings report?

Agios Pharma reported an EPS of -€1.508 in its last earnings report, missing expectations of -€1.477. Following the earnings report the stock price went down -2.564%.

Which hedge fund is a major shareholder of Agios Pharma?

Currently, no hedge funds are holding shares in DE:8AP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Agios Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

-35.67%

Trailing 12-Months

Asset Growth

-24.66%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Agios Pharma

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.

Agios Pharma (8AP) Earnings & Revenues

Historic Earnings Reports

8AP Company Deck

8AP Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call communicated substantial commercial momentum (AQVESME launch traction and U.S.-centric revenue), a meaningful near-term regulatory catalyst (Mitapivat PDUFA on Nov 1), and active pipeline expansion (cevidoplenib, AG-236, AG-181), supported by a strong cash position (~$1B). Offsetting these positives are elevated R&D and SG&A spending, a sizable net loss ($100.7M), quarter-to-quarter revenue variability (including a one-time $5M stocking benefit in Q2), and potential pricing/net revenue pressures for a sickle cell indication due to higher Medicaid mix and rebates. On balance, the operational and pipeline progress and the regulatory catalyst outweigh the financial and visibility challenges.View all DE:8AP earnings summaries

8AP Stock 12 Month Forecast

Average Price Target

€40.34

▲(39.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","50":"€50","28.25":"€28.3","35.5":"€35.5","42.75":"€42.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49.08220735,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€49.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.336650404,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€40.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.55692064,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€28.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,28.25,35.5,42.75,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.4,30.91401595,32.4280319,33.942047849999994,35.456063799999995,36.97007975,38.4840957,39.99811165,41.5121276,43.02614355,44.5401595,46.05417545,47.568191399999996,{"y":49.08220735,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.4,30.241280800307692,31.08256160061538,31.923842400923075,32.765123201230764,33.60640400153846,34.44768480184615,35.288965602153844,36.13024640246154,36.97152720276923,37.812808003076924,38.65408880338461,39.4953696036923,{"y":40.336650404,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.4,29.33514774153846,29.27029548307692,29.205443224615383,29.140590966153844,29.075738707692306,29.010886449230767,28.946034190769232,28.881181932307694,28.816329673846155,28.751477415384617,28.68662515692308,28.62177289846154,{"y":28.55692064,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.4,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >